This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
present document | 956 |
food safety | 661 |
european food | 654 |
safety authority | 651 |
public health | 437 |
conclusions reached | 324 |
issues addressed | 323 |
transparency principle | 323 |
output adopted | 323 |
published complying | 323 |
bodies identified | 310 |
without prejudice | 308 |
member states | 274 |
mg kg | 261 |
european countries | 261 |
authority reserves | 242 |
awarded following | 242 |
tender procedure | 242 |
abstract background | 184 |
european union | 169 |
plant mirnas | 160 |
risk factors | 160 |
kg cu | 155 |
european commission | 143 |
clinical trials | 142 |
breast cancer | 135 |
infectious diseases | 118 |
climate change | 117 |
job satisfaction | 117 |
working conditions | 112 |
united states | 110 |
exogenous ncrnas | 107 |
steering committee | 104 |
data protection | 100 |
efsa supporting | 95 |
supporting publication | 95 |
higher education | 92 |
learning objectives | 88 |
grant agreement | 86 |
united kingdom | 85 |
may also | 85 |
efsa reserves | 81 |
health care | 81 |
us fda | 79 |
blood pressure | 78 |
exogenous rnas | 77 |
logistic regression | 77 |
medicinal products | 72 |
food systems | 71 |
world health | 70 |
cord uid | 66 |
lung cancer | 66 |
doc id | 66 |
increased risk | 65 |
rs rs | 65 |
risk assessment | 65 |
personal data | 64 |
gi tract | 64 |
biological control | 64 |
study ch | 63 |
gastrointestinal tract | 62 |
health organization | 62 |
member state | 61 |
imaging techniques | 59 |
immune system | 59 |
cancer risk | 59 |
differential diagnosis | 59 |
key words | 58 |
respiratory syndrome | 57 |
new zealand | 57 |
wild boar | 56 |
european bat | 56 |
plant ncrnas | 56 |
economic growth | 55 |
publications efsa | 55 |
eu publications | 55 |
imaging modalities | 55 |
risk factor | 53 |
per cent | 53 |
health policy | 53 |
cohort study | 52 |
important role | 52 |
european parliament | 51 |
across europe | 51 |
working group | 51 |
breast milk | 51 |
become familiar | 51 |
bat species | 50 |
terrorist attacks | 49 |
eu member | 48 |
immune response | 47 |
clinical practice | 47 |
rare diseases | 46 |
exogenous plant | 46 |
literature search | 46 |
internal market | 45 |
disease control | 45 |
epidemiological studies | 45 |
wild boars | 44 |
ich regions | 44 |
supply chains | 44 |
literature review | 44 |
metabolic syndrome | 44 |
magnetic resonance | 44 |
small rnas | 44 |
presentation will | 44 |
european research | 44 |
chemically modified | 44 |
heart disease | 44 |
will also | 44 |
steel industry | 43 |
pet ct | 43 |
mr imaging | 43 |
isolation facilities | 43 |
social dimension | 42 |
social distancing | 42 |
imaging findings | 40 |
general population | 40 |
recent years | 40 |
exogenous rna | 40 |
growing pigs | 40 |
cellular uptake | 39 |
quality assurance | 39 |
high level | 39 |
different countries | 39 |
human rights | 38 |
nucleic acids | 38 |
energy efficiency | 38 |
biological effect | 38 |
european wild | 38 |
computed tomography | 38 |
high levels | 37 |
high risk | 37 |
copyright holder | 37 |
middle east | 37 |
coliform bacteria | 37 |
naked sirna | 37 |
radiation dose | 36 |
oral administration | 36 |
myocardial infarction | 36 |
large number | 36 |
excessive pricing | 35 |
biological effects | 35 |
even though | 35 |
developing countries | 35 |
data collection | 35 |
physical activity | 35 |
gene expression | 35 |
infectious disease | 35 |
european football | 34 |
coronavirus disease | 34 |
clinical trial | 34 |
next generation | 34 |
tourist arrivals | 34 |
cardiovascular disease | 34 |
kg feed | 34 |
rna molecules | 34 |
immune responses | 34 |
single market | 34 |
ich steering | 34 |
per year | 34 |
birth weight | 34 |
granted medrxiv | 33 |
author funder | 33 |
sectional study | 33 |
body weight | 33 |
key questions | 33 |
many countries | 32 |
coronary artery | 32 |
ambient intelligence | 32 |
sustainable development | 32 |
pharmaceutical regulations | 32 |
one study | 32 |
confirmed cases | 32 |
pandemic influenza | 32 |
biological fluids | 32 |
health services | 32 |
european medicines | 32 |
control group | 32 |
drug development | 32 |
laboratory rabbits | 32 |
health systems | 32 |
cardiovascular risk | 32 |
statistically significant | 32 |
gene silencing | 32 |
disease prevention | 31 |
new cases | 31 |
may lead | 31 |
national dras | 31 |
version posted | 31 |
european community | 31 |
research policy | 31 |
gut microbiota | 31 |
policy makers | 31 |
european bats | 31 |
spillover effects | 30 |
epithelial cells | 30 |
colorectal cancer | 30 |
acute respiratory | 30 |
eu health | 30 |
regression analysis | 30 |
gremmeniella abietina | 30 |
significant differences | 30 |
low levels | 30 |
bat lyssavirus | 30 |
control study | 30 |
transfer fees | 30 |
first step | 29 |
stroke care | 29 |
storyline elements | 29 |
wage inequality | 29 |
primary care | 29 |
body mass | 29 |
marketing authorization | 29 |
total number | 28 |
total rna | 28 |
sectional imaging | 28 |
interventional radiology | 28 |
national health | 28 |
control measures | 28 |
last years | 28 |
medical imaging | 28 |
eu countries | 28 |
small rna | 28 |
took place | 28 |
ich guidelines | 28 |
new technologies | 28 |
mammalian cells | 27 |
widely used | 27 |
european economic | 27 |
pharmaceutical products | 27 |
coronary heart | 27 |
emergency powers | 27 |
imaging modality | 27 |
image quality | 27 |
extracellular vesicles | 27 |
years ago | 27 |
adverse effects | 26 |
european centre | 26 |
protective equipment | 26 |
human plasma | 26 |
across countries | 26 |
european region | 26 |
regulatory authorities | 26 |
dietary exogenous | 26 |
decision making | 26 |
weighted imaging | 26 |
imaging technique | 26 |
imaging biomarkers | 26 |
sovereign bonds | 26 |
population density | 26 |
medicines agency | 26 |
mass index | 26 |
diagnostic imaging | 26 |
confidence interval | 25 |
infection control | 25 |
nucleic acid | 25 |
working groups | 25 |
generation eu | 25 |
eu research | 25 |
european agriculture | 25 |
wide range | 25 |
developed countries | 25 |
small intestine | 25 |
resonance imaging | 25 |
infectious agents | 25 |
among countries | 25 |
mental health | 25 |
diagnostic tests | 24 |
clinical studies | 24 |
consumer protection | 24 |
functional imaging | 24 |
quality control | 24 |
intensive care | 24 |
national level | 24 |
different types | 24 |
case reports | 24 |
economic activity | 24 |
age groups | 24 |
rare disease | 24 |
soft tissue | 24 |
plant mirna | 24 |
united nations | 24 |
alcohol consumption | 24 |
european pharmaceutical | 24 |
higher risk | 24 |
international standards | 24 |
european level | 24 |
stock market | 24 |
tourism sector | 24 |
supplementary material | 24 |
gm plants | 24 |
stranded rna | 24 |
odds ratios | 24 |
heart failure | 24 |
made available | 24 |
health information | 24 |
molecular imaging | 23 |
confidence intervals | 23 |
oral delivery | 23 |
health mandate | 23 |
artery disease | 23 |
past years | 23 |
long term | 23 |
private sector | 23 |
value chains | 23 |
technical requirements | 23 |
among women | 23 |
tumour response | 23 |
risk management | 23 |
foreign aid | 23 |
harmonization initiatives | 23 |
significantly higher | 23 |
filtering methods | 23 |
highly infectious | 23 |
institutional context | 23 |
informed consent | 23 |
innate immune | 23 |
creative commons | 23 |
blood flow | 23 |
key role | 23 |
results show | 22 |
incidental findings | 22 |
european donors | 22 |
european network | 22 |
health problems | 22 |
cancer screening | 22 |
broiler diets | 22 |
income countries | 22 |
second wave | 22 |
pharmaceutical companies | 22 |
peer review | 22 |
cu kg | 22 |
missed opportunity | 22 |
land use | 22 |
eastern europe | 22 |
eu ets | 22 |
breakthrough technologies | 22 |
session will | 22 |
one hand | 22 |
myxoma virus | 22 |
mg cu | 22 |
personal protective | 22 |
stroke patients | 22 |
innovation policy | 22 |
risk locus | 22 |
directive ec | 22 |
will review | 22 |
green deal | 22 |
six months | 22 |
transfer fee | 22 |
community structure | 22 |
exogenous ncrna | 22 |
mortality rates | 22 |
wild rabbit | 22 |
saudi arabia | 21 |
systematic review | 21 |
directive eec | 21 |
several studies | 21 |
bound copper | 21 |
global cooperation | 21 |
rna interference | 21 |
patient care | 21 |
regression models | 21 |
financial crisis | 21 |
prostate cancer | 21 |
working party | 21 |
oryctolagus cuniculus | 21 |
women aged | 21 |
early detection | 21 |
north america | 21 |
tumour size | 21 |
will provide | 21 |
air pollution | 21 |
bat lyssaviruses | 21 |
cervical cancer | 21 |
social media | 21 |
take place | 21 |
previous years | 21 |
significantly reduced | 21 |
long time | 21 |
lecture will | 21 |
last decade | 21 |
odds ratio | 21 |
body composition | 21 |
health system | 21 |
mean age | 20 |
may cause | 20 |
clinical information | 20 |
drug regulatory | 20 |
dynamic contrast | 20 |
economic development | 20 |
endovascular treatment | 20 |
haemorrhagic disease | 20 |
countries according | 20 |
vast majority | 20 |
relevant information | 20 |
dg sanco | 20 |
east respiratory | 20 |
south korea | 20 |
diagnostic rate | 20 |
steel production | 20 |
severe acute | 20 |
dietary plant | 20 |
lyssavirus type | 20 |
recent studies | 20 |
within europe | 20 |
european science | 20 |
significant reduction | 20 |
intracellular trafficking | 20 |
premier league | 20 |
growth rate | 20 |
differences among | 20 |
capillaria hepatica | 20 |
labor market | 20 |
cardiovascular diseases | 20 |
wild rabbits | 20 |
pharmaceutical industry | 20 |
global health | 20 |
bologna process | 20 |
czech republic | 20 |
also used | 20 |
novel coronavirus | 20 |
industrial policy | 20 |
across european | 20 |
protection directive | 20 |
boar populations | 20 |
will discuss | 19 |
prospective cohort | 19 |
environmental policies | 19 |
diagnostic accuracy | 19 |
health effects | 19 |
plant rna | 19 |
circular economy | 19 |
type i | 19 |
social distance | 19 |
international license | 19 |
million people | 19 |
future developments | 19 |
coronavirus outbreak | 19 |
intellectual property | 19 |
ch experiment | 19 |
imaging plays | 19 |
plant ncrna | 19 |
clinical audit | 19 |
concept paper | 19 |
gizzard erosion | 19 |
ad hoc | 19 |
bond yields | 19 |
development goals | 19 |
imaging methods | 19 |
per day | 19 |
may help | 19 |
contrast agents | 19 |
health professionals | 19 |
minimally invasive | 19 |
health emergency | 19 |
may affect | 19 |
first time | 19 |
time series | 19 |
public support | 19 |
respiratory diseases | 19 |
future research | 18 |
border closures | 18 |
biological barriers | 18 |
scientific literature | 18 |
highly pathogenic | 18 |
technological innovation | 18 |
will increase | 18 |
clinical data | 18 |
social environment | 18 |
health protection | 18 |
international trade | 18 |
socioeconomic pathways | 18 |
different imaging | 18 |
international health | 18 |
vascular disease | 18 |
added value | 18 |
cancer patients | 18 |
data collected | 18 |
per capita | 18 |
reported cases | 18 |
scientific advice | 18 |
periodate oxidation | 18 |
service providers | 18 |
mutual recognition | 18 |
natural resources | 18 |
linear regression | 18 |
greenhouse gas | 18 |
based gm | 18 |
side effects | 18 |
health status | 18 |
communicable diseases | 18 |
international cooperation | 18 |
best practices | 18 |
previous studies | 18 |
incidence rates | 18 |
mice fed | 18 |
active cases | 18 |
mouse model | 18 |
factors associated | 18 |
drug shortages | 18 |
rural areas | 18 |
plant mir | 18 |
protection law | 18 |
two different | 18 |
speculative bubble | 18 |
may increase | 18 |
containment measures | 18 |
web accessibility | 18 |
avian influenza | 18 |
legal framework | 18 |
west africa | 18 |
regulatory harmonization | 18 |
data processing | 18 |
i will | 17 |
storyline development | 17 |
financial markets | 17 |
nuclear medicine | 17 |
dendritic cells | 17 |
european race | 17 |
also provides | 17 |
time period | 17 |
energy consumption | 17 |
closely related | 17 |
best practice | 17 |
pharmaceutical regulation | 17 |
may occur | 17 |
medical products | 17 |
research area | 17 |
colon cancer | 17 |
orally administered | 17 |
health policies | 17 |
food security | 17 |
whole body | 17 |
dental caries | 17 |
action plan | 17 |
african countries | 17 |
small bowel | 17 |
sovereign bond | 17 |
innovation systems | 17 |
human use | 17 |
based therapeutics | 17 |
football clubs | 17 |
private law | 17 |
shared socioeconomic | 17 |
predictive value | 17 |
acute stroke | 17 |
natural selection | 17 |
high quality | 17 |
hypersensitivity pneumonitis | 17 |
exogenous mirnas | 17 |
global harmonization | 17 |
may provide | 17 |
cancer registry | 17 |
mirna processing | 17 |
renewable energy | 17 |
cancer mortality | 17 |
regional office | 17 |
asylum seekers | 17 |
gold standard | 17 |
humanitarian assistance | 17 |
free movement | 17 |
occupational exposure | 17 |
plasma samples | 17 |
fossil fuels | 17 |
control diet | 17 |
eu uk | 17 |
based medicine | 17 |
innovation system | 17 |
centralized procedure | 17 |
central european | 16 |
synthetic mir | 16 |
may reduce | 16 |
missing data | 16 |
milk exosomes | 16 |
care providers | 16 |
business plan | 16 |
ct angiography | 16 |
different levels | 16 |
native dutch | 16 |
rights reserved | 16 |
without permission | 16 |
may result | 16 |
amino acids | 16 |
health authorities | 16 |
multidisciplinary team | 16 |
mouth disease | 16 |
natural enemies | 16 |
available information | 16 |
lung disease | 16 |
dominant position | 16 |
baseline information | 16 |
will become | 16 |
air quality | 16 |
treatment response | 16 |
patient data | 16 |
reuse allowed | 16 |
clinical applications | 16 |
particularly important | 16 |
dietary intake | 16 |
data subject | 16 |
similar results | 16 |
health crisis | 16 |
respiratory symptoms | 16 |
many different | 16 |
bat rabies | 16 |
rcd virus | 16 |
perfusion imaging | 16 |
one year | 16 |
harmonization activities | 16 |
infected people | 16 |
viral rna | 16 |
significantly lower | 16 |
economic crisis | 16 |
disease virus | 16 |
bacterial species | 16 |
see also | 16 |
bone marrow | 16 |
also important | 16 |
sus scrofa | 16 |
will need | 16 |
international organizations | 16 |
animal models | 16 |
see table | 16 |
near future | 16 |
study design | 16 |
will focus | 16 |
plasma levels | 16 |
european country | 16 |
mathematical model | 16 |
skull base | 16 |
year old | 16 |
allowed without | 16 |
two months | 16 |
ich process | 16 |
one country | 16 |
radiation exposure | 16 |
global economy | 16 |
natural history | 15 |
immune cells | 15 |
among others | 15 |
many cases | 15 |
saharan africa | 15 |
european stock | 15 |
supply chain | 15 |
general practice | 15 |
also showed | 15 |
see section | 15 |
genetically modified | 15 |
literature arguing | 15 |
cystic lesions | 15 |
additional information | 15 |
like receptor | 15 |
another study | 15 |
annex glands | 15 |
piglets fed | 15 |
cognitive function | 15 |
performed using | 15 |
confirmed covid | 15 |
better understanding | 15 |
observational studies | 15 |
thermal ablation | 15 |
available evidence | 15 |
rabbit populations | 15 |
information systems | 15 |
european green | 15 |
derived exogenous | 15 |
significantly increased | 15 |
european institutions | 15 |
fatty acids | 15 |
authors declare | 15 |
human body | 15 |
aged years | 15 |
relative risk | 15 |
different european | 15 |
impact assessment | 15 |
fecal samples | 15 |
possible sensitization | 15 |
network filtering | 15 |
environmental efforts | 15 |
country i | 15 |
tourism industry | 15 |
per country | 15 |
cox proportional | 15 |
pregnant women | 15 |
policy outputs | 15 |
small number | 15 |
will take | 15 |
family history | 15 |
significant effect | 15 |
five years | 15 |
epidemiological research | 15 |
rna silencing | 15 |
regression model | 15 |
privacy protection | 15 |
arterial disease | 15 |
individual countries | 15 |
medicines regulatory | 14 |
human populations | 14 |
immune function | 14 |
european states | 14 |
pharmaceutical system | 14 |
traditional medicines | 14 |
making process | 14 |
among european | 14 |
change mitigation | 14 |
decision makers | 14 |
regional harmonization | 14 |
bowel disease | 14 |
eu public | 14 |
cardiac ct | 14 |
eu policy | 14 |
contrast media | 14 |
faecal samples | 14 |
first years | 14 |
economic consequences | 14 |
emission reduction | 14 |
floor pens | 14 |
global value | 14 |
throughout europe | 14 |
si content | 14 |
positive selection | 14 |
resource exporters | 14 |
breast imaging | 14 |
fluid collections | 14 |
renal function | 14 |
blood samples | 14 |
global pandemic | 14 |
radiation protection | 14 |
european society | 14 |
drug administration | 14 |
domestic pigs | 14 |
region transmission | 14 |
development process | 14 |
may become | 14 |
control fed | 14 |
vertebrate pests | 14 |
years old | 14 |
lifestyle factors | 14 |
brain tumours | 14 |
environmental factors | 14 |
substitution effect | 14 |
bone tumours | 14 |
medrxiv preprint | 14 |
national regulatory | 14 |
domestic animals | 14 |
two groups | 14 |
treatment options | 14 |
results suggest | 14 |
commonly used | 14 |
emerging infectious | 14 |
present study | 14 |
population dynamics | 14 |
financial support | 14 |
healthcare professionals | 14 |
green recovery | 14 |
contrast enhancement | 14 |
respiratory sensitization | 14 |
national governments | 14 |
screening programme | 14 |
copper concentrations | 14 |
countries inequality | 14 |
experimental animals | 14 |
systemic effects | 14 |
copper sources | 14 |
response rate | 14 |
liver metastases | 14 |
derived mirnas | 14 |
european integration | 14 |
core group | 13 |
crucial role | 13 |
emerging viruses | 13 |
spinal cord | 13 |
close contacts | 13 |
previous research | 13 |
different regions | 13 |
key question | 13 |
controlled trials | 13 |
will continue | 13 |
significantly associated | 13 |
microbial community | 13 |
preliminary results | 13 |
much higher | 13 |
regulatory pathways | 13 |
genetic variants | 13 |
hazard ratio | 13 |
regulatory requirements | 13 |
contrast agent | 13 |
technological change | 13 |
least one | 13 |
gas emissions | 13 |
communicable disease | 13 |
data analysis | 13 |
health threats | 13 |
european regions | 13 |
nervous system | 13 |
chemical modifications | 13 |
birth cohort | 13 |
radiofrequency ablation | 13 |
influenza pandemic | 13 |
excessive prices | 13 |
worth noting | 13 |
world bank | 13 |
autoimmune diseases | 13 |
feed risk | 13 |
harmonization process | 13 |
gross domestic | 13 |
virus infection | 13 |
inflammatory diseases | 13 |
energy transition | 13 |
pharmaceutical sector | 13 |
patient management | 13 |
sexually transmitted | 13 |
relative survival | 13 |
percentage points | 13 |
useful tool | 13 |
social support | 13 |
recipient countries | 13 |
poisson regression | 13 |
spatial resolution | 13 |
herd immunity | 13 |
stock markets | 13 |
coronary cta | 13 |
data suggest | 13 |
energy policy | 13 |
case study | 13 |
allergic diseases | 13 |
cvd risk | 13 |
global fund | 13 |
growth factor | 13 |
arabidopsis thaliana | 13 |
pharmaceutical market | 13 |
worth mentioning | 13 |
harmonization initiative | 13 |
health research | 13 |
naturally occurring | 13 |
fossil fuel | 13 |
represented groups | 13 |
ex vivo | 13 |
host population | 13 |
technical aspects | 13 |
outside europe | 13 |
cancer cases | 13 |
work intensity | 13 |
health problem | 13 |
east asia | 13 |
health service | 13 |
molecular mechanisms | 13 |
venous thrombosis | 13 |
review process | 13 |
financial stability | 13 |
regulatory agencies | 13 |
empirical evidence | 13 |
surveillance systems | 13 |
fold higher | 13 |
efsa task | 13 |
sir model | 13 |
horizon europe | 13 |
cardiovascular events | 13 |
health law | 13 |
per cell | 13 |
low carbon | 13 |
product development | 13 |
will help | 13 |
many years | 13 |
reported data | 13 |
genetic variation | 13 |
respiratory sensitizers | 13 |
heart rate | 13 |
among patients | 13 |
risk perception | 13 |
containment policies | 13 |
using data | 13 |
prognostic factors | 12 |
essential medicines | 12 |
pet imaging | 12 |
cell cultures | 12 |
cell carcinoma | 12 |
satisfaction across | 12 |
directly related | 12 |
molecular weight | 12 |
co emissions | 12 |
will require | 12 |
epidemic situation | 12 |
diet supplemented | 12 |
nursing homes | 12 |
regulatory systems | 12 |
targeted therapies | 12 |
pest populations | 12 |
higher levels | 12 |
will certainly | 12 |
plant exogenous | 12 |
gene therapy | 12 |
special focus | 12 |
economic impact | 12 |
methodology described | 12 |
amino acid | 12 |
evidence suggests | 12 |
will lead | 12 |
deep decarbonisation | 12 |
available data | 12 |
tourism demand | 12 |
nan doi | 12 |
white matter | 12 |
statistical analysis | 12 |
transmission rates | 12 |
zika virus | 12 |
early stage | 12 |
hospital admissions | 12 |
urease activity | 12 |
uric acid | 12 |
socioeconomic status | 12 |
regulatory framework | 12 |
reproductive number | 12 |
latin america | 12 |
findings suggest | 12 |
effect size | 12 |
technological development | 12 |
population growth | 12 |
iv injection | 12 |
chronic diseases | 12 |
porcine reproductive | 12 |
healthcare workers | 12 |
high degree | 12 |
seroprevalence rates | 12 |
european rabbits | 12 |
maastricht treaty | 12 |
standard deviation | 12 |
eu level | 12 |
physical environment | 12 |
following key | 12 |
circulatory system | 12 |
economic constitution | 12 |
determine whether | 12 |
based case | 12 |
atopic dermatitis | 12 |
western europe | 12 |
noncoding rna | 12 |
ileal content | 12 |
results indicate | 12 |
different databases | 12 |
target tissue | 12 |
individual patient | 12 |
clinical symptoms | 12 |
estimated using | 12 |
labour market | 12 |
cerebrovascular disease | 12 |
intervention group | 12 |
national law | 12 |
treatment planning | 12 |
latin american | 12 |
wide variety | 12 |
european public | 12 |
initial search | 12 |
last decades | 12 |
committee meeting | 12 |
often used | 12 |
real time | 12 |
animal health | 12 |
positive results | 12 |
patients without | 12 |
passive smoking | 12 |
knee arthroplasty | 12 |
also developed | 12 |
three regions | 12 |
lwa index | 12 |
general public | 12 |
lymph node | 12 |
also increased | 12 |
health impact | 12 |
degree centrality | 12 |
response criteria | 12 |
birds fed | 12 |
two years | 12 |
medical staff | 12 |
first phase | 12 |
different populations | 12 |
national laws | 12 |
domestic product | 12 |
quality medicines | 12 |
urban areas | 12 |
relatively high | 12 |
circular rnas | 12 |
countries within | 12 |
accurate diagnosis | 12 |
significant increase | 12 |
strict liability | 12 |
environmental challenges | 12 |
clinical research | 12 |
lessons learned | 12 |
growth rates | 12 |
honeysuckle decoction | 12 |
cross sectional | 12 |
european energy | 12 |
border control | 12 |
common market | 12 |
web content | 11 |
provide information | 11 |
diabetic patients | 11 |
effect sizes | 11 |
low concentrations | 11 |
guidance documents | 11 |
value chain | 11 |
long noncoding | 11 |
also established | 11 |
well known | 11 |
eu budget | 11 |
information sharing | 11 |
pandemic disease | 11 |
key elements | 11 |
rotator cuff | 11 |
health monitoring | 11 |
similarity coefficient | 11 |
copper concentration | 11 |
hiv aids | 11 |
international collaboration | 11 |
climate policy | 11 |
stem cells | 11 |
available literature | 11 |
state aid | 11 |
antisense oligonucleotides | 11 |
integration process | 11 |
political instability | 11 |
cash inflows | 11 |
regulatory network | 11 |
ghg emission | 11 |
clay bound | 11 |
health powers | 11 |
ct imaging | 11 |
influenza virus | 11 |
team members | 11 |
age group | 11 |
energy companies | 11 |
production networks | 11 |
european higher | 11 |
food feed | 11 |
power sector | 11 |
body fluids | 11 |
cerebral blood | 11 |
pivotal role | 11 |
technical assistance | 11 |
border controls | 11 |
drinking water | 11 |
copper seems | 11 |
economic integration | 11 |
negative impact | 11 |
financial resources | 11 |
risk analysis | 11 |
selection bias | 11 |
unemployment rate | 11 |
syndrome coronavirus | 11 |
ct perfusion | 11 |
relatively low | 11 |
information society | 11 |
cell culture | 11 |
gut content | 11 |
bilateral cooperation | 11 |
mr pet | 11 |
new york | 11 |
affected countries | 11 |
research group | 11 |
bovine tuberculosis | 11 |
ami world | 11 |
mortality rate | 11 |
case studies | 11 |
derived ncrnas | 11 |
like nanoparticles | 11 |
medical treatment | 11 |
may contribute | 11 |
global warming | 11 |
childhood cancer | 11 |
several countries | 11 |
specific differences | 11 |
inflammatory bowel | 11 |
environmental policy | 11 |
diabetes mellitus | 11 |
weighted images | 11 |
risk patients | 11 |
current state | 11 |
european economy | 11 |
ulcerative colitis | 11 |
mainly due | 11 |
current knowledge | 11 |
radiation therapy | 11 |
term exposure | 11 |
gastric cancer | 11 |
clearly defined | 11 |
spect ct | 11 |
spanning tree | 11 |
also included | 11 |
children aged | 11 |
lymph nodes | 11 |
based energy | 11 |
research institutions | 11 |
pharmaceutical product | 11 |
lassa fever | 11 |
southern europe | 11 |
results obtained | 11 |
fed birds | 11 |
new areas | 11 |
economic value | 11 |
loss rate | 11 |
publicly available | 11 |
minsky model | 11 |
lockdown measures | 11 |
randomized controlled | 11 |
dialysis patients | 11 |
good manufacturing | 11 |
brown tree | 11 |
national authorities | 11 |
important step | 11 |
brain barrier | 11 |
scenario development | 11 |
experimental diets | 11 |
identity management | 11 |
general practitioner | 11 |
earlier studies | 11 |
european citizens | 11 |
medical countermeasures | 11 |
errors detected | 11 |
law applicable | 11 |
cancer incidence | 11 |
contrast medium | 11 |
animal studies | 11 |
pediatric emergency | 11 |
negative pressure | 11 |
naked sirnas | 11 |
first wave | 11 |
finally selected | 11 |
diagnostic workup | 11 |
education institutions | 11 |
medical devices | 11 |
health assembly | 11 |
general health | 11 |
stakeholder groups | 11 |
also lead | 11 |
south america | 11 |
private sectors | 11 |
three months | 11 |
ionising radiation | 11 |
population structure | 11 |
high demand | 11 |
states food | 11 |
control agents | 11 |
copper bound | 11 |
potential confounders | 11 |
management board | 11 |
six european | 11 |
technical cooperation | 11 |
service provider | 11 |
mortality risk | 11 |
also allows | 11 |
weather conditions | 11 |
direct contact | 11 |
health organisation | 10 |
dietary exposure | 10 |
zealand white | 10 |
emergency use | 10 |
pharmaceutical domain | 10 |
high concentrations | 10 |
rabbit haemorrhagic | 10 |
food supply | 10 |
hypersensitivity reactions | 10 |
capacity building | 10 |
south africa | 10 |
will include | 10 |
health indicators | 10 |
reputation systems | 10 |
collected data | 10 |
starch methionine | 10 |
serum levels | 10 |
large amount | 10 |
among men | 10 |
pigs fed | 10 |
health issues | 10 |
tyrosine kinase | 10 |
current situation | 10 |
technical document | 10 |
health outcomes | 10 |
certain types | 10 |
fold increase | 10 |
annual review | 10 |
coronary ct | 10 |
predictive ability | 10 |
tree snake | 10 |
health relevant | 10 |
satisfaction among | 10 |
mean loss | 10 |
modified rnas | 10 |
ischemic stroke | 10 |
exchange information | 10 |
positron emission | 10 |
contact tracing | 10 |
multivariate logistic | 10 |
public transport | 10 |
article tfeu | 10 |
framework programme | 10 |
debt crisis | 10 |
using different | 10 |
north american | 10 |
central role | 10 |
local recurrence | 10 |
will allow | 10 |
focused ultrasound | 10 |
wage loss | 10 |
susceptible population | 10 |
randomly selected | 10 |
social networks | 10 |
european data | 10 |
health data | 10 |
functional information | 10 |
content accessibility | 10 |
positive impact | 10 |
increased prevalence | 10 |
care workers | 10 |
type diabetes | 10 |
st century | 10 |
eu states | 10 |
economic conditions | 10 |
good example | 10 |
eastern european | 10 |
two weeks | 10 |
patient dose | 10 |
term effects | 10 |
regional level | 10 |
herbal medicines | 10 |
emergency department | 10 |
technical equipment | 10 |
main objective | 10 |
management systems | 10 |
innate immunity | 10 |
technology development | 10 |
four different | 10 |
vice versa | 10 |
allergic reactions | 10 |
currently available | 10 |
study population | 10 |
environmental protection | 10 |
central nervous | 10 |
public opinion | 10 |
million inhabitants | 10 |
future development | 10 |
european council | 10 |
reservoir hosts | 10 |
text reports | 10 |
increased incidence | 10 |
work together | 10 |
lisbon treaty | 10 |
major public | 10 |
international harmonization | 10 |
european populations | 10 |
competent authorities | 10 |
modified sirna | 10 |
technical guidelines | 10 |
health regulations | 10 |
also known | 10 |
final demand | 10 |
folate intake | 10 |
statistical analyses | 10 |
european steel | 10 |
terrorist events | 10 |
adverse events | 10 |
allows us | 10 |
group differences | 10 |
blood volume | 10 |
may need | 10 |
member countries | 10 |
european system | 10 |
attacks perpetrated | 10 |
animal feed | 10 |
modern humans | 10 |
rapidly degraded | 10 |
possible biological | 10 |
memory effect | 10 |
policy responses | 10 |
emergency departments | 10 |
see supplementary | 10 |
cohort studies | 10 |
life sciences | 10 |
pilot projects | 10 |
eu national | 10 |
infant mortality | 10 |
step towards | 10 |
human resources | 10 |
specific topics | 10 |
environmental standards | 10 |
postmenopausal women | 10 |
steel sector | 10 |
risk profile | 10 |
partial functioning | 10 |
acute myocardial | 10 |
plant micrornas | 10 |
infection rates | 10 |
feed additive | 10 |
might also | 10 |
future studies | 10 |
cox regression | 10 |
eu will | 10 |
free trade | 10 |
interest groups | 10 |
also observed | 10 |
whenever possible | 10 |
lower levels | 10 |
weight gain | 10 |
beam ct | 10 |
public authorities | 10 |
intermediate goods | 10 |
bovine milk | 10 |
host range | 10 |
efficacy data | 10 |
animal rule | 10 |
environmental impacts | 10 |
pathological conditions | 10 |
study conducted | 10 |
session objectives | 10 |
global supply | 10 |
within countries | 10 |
interventional procedures | 10 |
interventional oncology | 10 |
inversely associated | 10 |
dna methylation | 10 |
commons licence | 10 |
survival rates | 10 |
directorate general | 10 |
marketing application | 10 |
two studies | 10 |
better understand | 10 |
chain reaction | 10 |
patient groups | 10 |
economic pathways | 10 |
eu i | 10 |
euro area | 10 |
years later | 10 |
control studies | 10 |
stakeholder engagement | 10 |
disease activity | 10 |
vivo studies | 10 |
starting point | 10 |
rna polymerase | 10 |
random sample | 10 |
sm ii | 10 |
country offices | 10 |
multivariate analysis | 10 |
proportional hazard | 10 |
naked oligonucleotides | 10 |
regulatory convergence | 10 |
available online | 10 |
twenty years | 10 |
public policies | 10 |
accessibility guidelines | 10 |
imaging follow | 10 |
multiple myeloma | 10 |
transgenic plants | 10 |
adjusted odds | 10 |
price regulation | 10 |
clinical history | 10 |
correlation coefficients | 10 |
clinical use | 10 |
two main | 10 |
narrative review | 10 |
real cfr | 10 |
new european | 10 |
cell types | 10 |
regression analyses | 10 |
educational level | 10 |
working hours | 10 |
previously described | 10 |
will cover | 10 |
pancreatic cancer | 10 |
bone metastases | 10 |
supplemented diets | 9 |
weighted mri | 9 |
mri will | 9 |
social groups | 9 |
human immune | 9 |
market volatility | 9 |
european central | 9 |
scientific community | 9 |
imaging method | 9 |
higher among | 9 |
case count | 9 |
dependent variable | 9 |
broad range | 9 |
clinical presentation | 9 |
patient selection | 9 |
data show | 9 |
intended use | 9 |
industry decarbonisation | 9 |
data sets | 9 |
civil society | 9 |
one third | 9 |
third parties | 9 |
data will | 9 |
job security | 9 |
diets supplemented | 9 |
intermittent renewables | 9 |
different tissues | 9 |
knowledge society | 9 |
will give | 9 |
financial investors | 9 |
copper intake | 9 |
medicinal product | 9 |
health crises | 9 |
clinical efficacy | 9 |
thyroid nodules | 9 |
rna therapeutics | 9 |
referral centers | 9 |
national government | 9 |
three main | 9 |
advisor advocate | 9 |
identified key | 9 |
binding proteins | 9 |
differ significantly | 9 |
coronary calcium | 9 |
significant association | 9 |
epidemiological situation | 9 |
mouse populations | 9 |
conditions among | 9 |
proportional hazards | 9 |
primary prevention | 9 |
haemorrhagic fever | 9 |
policy instruments | 9 |
ami environment | 9 |
stringency index | 9 |
borne diseases | 9 |
data provided | 9 |
imaging features | 9 |
may change | 9 |
celiac disease | 9 |
work time | 9 |
like receptors | 9 |
biological agents | 9 |
new information | 9 |
expanded access | 9 |
attack rate | 9 |
surgical treatment | 9 |
patients aged | 9 |
per group | 9 |
preparedness plans | 9 |
piglet diets | 9 |
negative correlation | 9 |
open access | 9 |
pcr assays | 9 |
risk areas | 9 |
systematic literature | 9 |
billion euros | 9 |
population based | 9 |
may vary | 9 |
chest pain | 9 |
specific types | 9 |
coding rnas | 9 |
related factors | 9 |
first year | 9 |
standard errors | 9 |
detailed information | 9 |
health advisor | 9 |
ghg emissions | 9 |
care facilities | 9 |
health emergencies | 9 |
member economies | 9 |
ghg intensity | 9 |
lelystad isolate | 9 |
new data | 9 |
search engines | 9 |
abdominal injuries | 9 |
countries like | 9 |
evolutionary processes | 9 |
electronic communication | 9 |
rna content | 9 |
evolutionary pressure | 9 |
imaging studies | 9 |
supporting groups | 9 |
iv administration | 9 |
cuso significantly | 9 |
european rabbit | 9 |
death rate | 9 |
supplementary data | 9 |
zoonotic potential | 9 |
breast mri | 9 |
basic ssps | 9 |
antimicrobial resistance | 9 |
tuberculosis infection | 9 |
imaging may | 9 |
human genome | 9 |
education system | 9 |
potential impact | 9 |
country blocks | 9 |
extensive literature | 9 |
innovative technologies | 9 |
cluster analysis | 9 |
usual care | 9 |
daily practice | 9 |
unique opportunity | 9 |
renal failure | 9 |
kg day | 9 |
increasingly used | 9 |
global public | 9 |
access control | 9 |
initial number | 9 |
arabian peninsula | 9 |
ncrnas must | 9 |
higher level | 9 |
community mobility | 9 |
lamina propria | 9 |
may play | 9 |
hazard ratios | 9 |
information system | 9 |
missed opportunities | 9 |
administrative simplification | 9 |
shared socio | 9 |
different approaches | 9 |
new eu | 9 |
mirnas mir | 9 |
genetic diversity | 9 |
excess risk | 9 |
negative effects | 9 |
two countries | 9 |
several european | 9 |
imaging will | 9 |
hendra virus | 9 |
industrial production | 9 |
disease risk | 9 |
people living | 9 |
controlled trial | 9 |
best imaging | 9 |
life style | 9 |
will depend | 9 |
frequently used | 9 |
newcastle disease | 9 |
aid implementers | 9 |
average levels | 9 |
imaging protocols | 9 |
will affect | 9 |
individual level | 9 |
healthcare systems | 9 |
oesophageal cancer | 9 |
new legislation | 9 |
contractual obligations | 9 |
recent study | 9 |
host populations | 9 |
european private | 9 |
rectal cancer | 9 |
national security | 9 |
appropriate use | 9 |
international guidelines | 9 |
prevalence rates | 9 |
positively associated | 9 |
integrated assessments | 9 |
energy management | 9 |
ethanol intake | 9 |
rett syndrome | 9 |
important factor | 9 |
previous literature | 9 |
taken place | 9 |
population health | 9 |
precision medicine | 9 |
fewer deaths | 9 |
spin labelling | 9 |
detailed study | 9 |
legal order | 9 |
basic research | 9 |
will present | 9 |
consecutive patients | 9 |
interventional radiologists | 9 |
eu policies | 9 |
bacterial infection | 9 |
emission tomography | 9 |
haplotype block | 9 |
countries will | 9 |
circular rna | 9 |
may improve | 9 |
among different | 9 |
spanish population | 9 |
reference standard | 9 |
may include | 9 |
statin therapy | 9 |
test results | 9 |
football finance | 9 |
will address | 9 |
global environmental | 9 |
incident cases | 9 |
economic effects | 9 |
health survey | 9 |
property rights | 9 |
broiler chickens | 9 |
dm patients | 9 |
contrast errors | 9 |
techniques will | 9 |
privacy policies | 9 |
several years | 9 |
market rules | 9 |
demand due | 9 |
serum uric | 9 |
bakery workers | 9 |
care system | 9 |
emergency radiology | 9 |
first two | 9 |
response evaluation | 9 |
ovarian cancer | 9 |
outbreak detection | 9 |
analysis showed | 9 |
risk groups | 9 |
caesarean section | 9 |
full capacity | 9 |
special issue | 9 |
effect estimates | 9 |
crisis management | 9 |
clinical evaluation | 9 |
malignant lesions | 9 |
epidemiological data | 9 |
mg dl | 9 |
technical issues | 9 |
cause mortality | 9 |
also found | 9 |
eu institutions | 9 |
small ncrnas | 9 |
neuroendocrine tumours | 9 |
research institutes | 9 |
search using | 9 |
third countries | 9 |
marketing authorisation | 9 |
response assessment | 9 |
ncrna molecules | 9 |
brain tumour | 9 |
infected individuals | 9 |
oral route | 9 |
small size | 9 |
environmental pressures | 9 |
ten years | 9 |
similar class | 9 |
vascular diseases | 9 |
production organism | 9 |
ec eu | 9 |
vitro studies | 9 |
studies performed | 9 |
exposure levels | 9 |
lower risk | 9 |
world war | 9 |
diabetes patients | 9 |
healthy people | 9 |
time quality | 9 |
still unknown | 9 |
economic community | 9 |
wage losses | 9 |
disease will | 9 |
previous year | 9 |
new challenges | 9 |
take advantage | 9 |
heart diseases | 9 |
go beyond | 9 |
grand challenges | 9 |
recombination events | 9 |
procurement policies | 8 |
possible effects | 8 |
health products | 8 |
institutional characteristics | 8 |
susceptible cases | 8 |
agricultural policy | 8 |
rnai effects | 8 |
studies report | 8 |
harmonized standards | 8 |
law enforcement | 8 |
ich parties | 8 |
silencing effects | 8 |
technology innovation | 8 |
screening programmes | 8 |
speculative bubbles | 8 |
common technical | 8 |
considered appropriate | 8 |
vary across | 8 |
vascular risk | 8 |
computed using | 8 |
related mortality | 8 |
valley fever | 8 |
occupational asthma | 8 |
social characteristics | 8 |
baseline characteristics | 8 |
may influence | 8 |
dutch population | 8 |
poverty index | 8 |
methionine complex | 8 |
three countries | 8 |
life cycle | 8 |
early stages | 8 |
become available | 8 |
fever virus | 8 |
may show | 8 |
animal products | 8 |
actual data | 8 |
tight junctions | 8 |
integration model | 8 |
currently used | 8 |
abstract introduction | 8 |
relevant eu | 8 |
mortality among | 8 |
isolation units | 8 |
different sources | 8 |
northern italy | 8 |
metastatic disease | 8 |
remains unclear | 8 |
healthcare services | 8 |
different methods | 8 |
rna delivery | 8 |
breeding group | 8 |
clinical routine | 8 |
legal powers | 8 |
identified using | 8 |
european vespertilionid | 8 |
different aspects | 8 |
small cell | 8 |
environmental enrichment | 8 |
total cholesterol | 8 |
epizootic haemorrhagic | 8 |
small interfering | 8 |
public sector | 8 |
right ventricular | 8 |
suspected cases | 8 |
biometric data | 8 |
epidemiologic studies | 8 |
vocal cord | 8 |
high resolution | 8 |
three years | 8 |
nuclear imaging | 8 |
mean correlation | 8 |
new tools | 8 |
common pitfalls | 8 |
high blood | 8 |
also detected | 8 |
badger culling | 8 |
personal devices | 8 |
within one | 8 |
physical examination | 8 |
domestic rabbits | 8 |
immune activation | 8 |
taken together | 8 |
generation sequencing | 8 |
copper supplemented | 8 |
tobacco control | 8 |
will likely | 8 |
study showed | 8 |
international level | 8 |
tourism activity | 8 |
term economic | 8 |
integral part | 8 |
recovery programs | 8 |
patients treated | 8 |
bacterial infections | 8 |
regulatory system | 8 |
course will | 8 |
cumulative cases | 8 |
read counts | 8 |
grey literature | 8 |
national consortium | 8 |
posted june | 8 |
system will | 8 |
formulated version | 8 |
world economy | 8 |
acute renal | 8 |
ldlrap protein | 8 |
health situation | 8 |
aspergillus niger | 8 |
operational management | 8 |
pandemic will | 8 |
peripheral arterial | 8 |
plasma concentrations | 8 |
patient safety | 8 |
early phase | 8 |
revenue ratio | 8 |
social responsibility | 8 |
information exchange | 8 |
nordic countries | 8 |
pharmaceutical pricing | 8 |
ct scan | 8 |
routine clinical | 8 |
posted may | 8 |
kg copper | 8 |
cancer will | 8 |
different areas | 8 |
social committee | 8 |
sequence data | 8 |
species transmission | 8 |
electricity demand | 8 |
dietetically absorbed | 8 |
next step | 8 |
using cox | 8 |
classical swine | 8 |
nipah virus | 8 |
market share | 8 |
partial closure | 8 |
dark scenarios | 8 |
agent specimens | 8 |
active surveillance | 8 |
detailed analysis | 8 |
highest risk | 8 |
information regarding | 8 |
biological products | 8 |
high frequency | 8 |
scientific consensus | 8 |
older age | 8 |
large differences | 8 |
evidence base | 8 |
headcount poverty | 8 |
clinical medicine | 8 |
recist criteria | 8 |
industry associations | 8 |
respiratory tract | 8 |
second half | 8 |
main goal | 8 |
analysed using | 8 |
different parts | 8 |
studies suggest | 8 |
cu complex | 8 |
also provide | 8 |
supplementing piglet | 8 |
neighboring countries | 8 |
facilitated regulatory | 8 |
information technology | 8 |
central europe | 8 |
multiple logistic | 8 |
national public | 8 |
global challenges | 8 |
pulmonary embolism | 8 |
time horizon | 8 |
highest level | 8 |
ich gcg | 8 |
europe date | 8 |
age classes | 8 |
cranial nerves | 8 |
skin melanoma | 8 |
cellular barriers | 8 |
mr spectroscopy | 8 |
arterial spin | 8 |
market values | 8 |
article working | 8 |
episode sensitivity | 8 |
political will | 8 |
well established | 8 |
longer time | 8 |
silico work | 8 |
framework program | 8 |
caged rabbits | 8 |
health risk | 8 |
conditional logistic | 8 |
european population | 8 |
closed occupations | 8 |
fed mg | 8 |
economic recovery | 8 |
target gene | 8 |
measures taken | 8 |
freely available | 8 |
six countries | 8 |
important risk | 8 |
viral infections | 8 |
environmental regulation | 8 |
two major | 8 |
srna sequencing | 8 |
tis approach | 8 |
rift valley | 8 |
direct reduction | 8 |
mirnas levels | 8 |
breeding groups | 8 |
carbon emissions | 8 |
health interventions | 8 |
care systems | 8 |
provided information | 8 |
southern european | 8 |
vector autoregressive | 8 |
randomised controlled | 8 |
phylogenetic analysis | 8 |
working steps | 8 |
multiple sclerosis | 8 |
quality criteria | 8 |
investigate whether | 8 |
autoregressive model | 8 |
widely available | 8 |
pathogenic avian | 8 |
participating countries | 8 |
screening program | 8 |
hid patients | 8 |
confirmed case | 8 |
blood products | 8 |
imaging criteria | 8 |
may explain | 8 |
gmp inspections | 8 |
recovery packages | 8 |
foreign affairs | 8 |
intelligent agents | 8 |
adipose tissue | 8 |
high prevalence | 8 |
assessed using | 8 |
population size | 8 |
without compromising | 8 |
fertility control | 8 |
coronavirus pandemic | 8 |
central node | 8 |
qa policies | 8 |
different studies | 8 |
preparatory phase | 8 |
policy measures | 8 |
dietary mirnas | 8 |
squamous cell | 8 |
health ministers | 8 |
experimental infection | 8 |
study reported | 8 |
manifest vascular | 8 |
new imaging | 8 |
also includes | 8 |
structured reporting | 8 |
knowledge base | 8 |
finance annual | 8 |
risk population | 8 |
international conference | 8 |
smoking prevalence | 8 |
new approach | 8 |
co eq | 8 |
might lead | 8 |
delivery systems | 8 |
protective effect | 8 |
policy making | 8 |
pulmonary artery | 8 |
liver tumours | 8 |
liver disease | 8 |
global ssps | 8 |
year period | 8 |
government response | 8 |
ich secretariat | 8 |
patient access | 8 |
global level | 8 |
outcome measures | 8 |
cell line | 8 |
coronary arteries | 8 |
human breast | 8 |
vertebrate pest | 8 |
student body | 8 |
different species | 8 |
study results | 8 |
common cause | 8 |
kg cuso | 8 |
delivery vehicles | 8 |
health concerns | 8 |
methods used | 8 |
three ich | 8 |
provide additional | 8 |
oral health | 8 |
transmitted diseases | 8 |
data available | 8 |
cell surface | 8 |
viable tumour | 8 |
may present | 8 |
recovery plan | 8 |
good clinical | 8 |
reactive protein | 8 |
best available | 8 |
food system | 8 |
appropriate handling | 8 |
supporting group | 8 |
needle biopsy | 8 |
diastolic blood | 8 |
western pomerania | 8 |
selective pressure | 8 |
laboratory animals | 8 |
sovereign debt | 8 |
public procurement | 8 |
collaborating centers | 8 |
relatively small | 8 |
mirna duplex | 8 |
observational study | 8 |
risk stratification | 8 |
located within | 8 |
information security | 8 |
stimulus packages | 8 |
special attention | 8 |
available scientific | 8 |
tourism organization | 8 |
also play | 8 |
administered orally | 8 |
resource use | 8 |
normal variants | 8 |
european health | 8 |
also available | 8 |
distance index | 8 |
colombian study | 8 |
tourism destinations | 8 |
emergency medicine | 8 |
important part | 8 |
hid cases | 8 |
factors influencing | 8 |
football market | 8 |
cell lines | 8 |
still unclear | 8 |
inflammatory response | 8 |
slightly modified | 8 |
mirna biogenesis | 8 |
material efficiency | 8 |
executive board | 8 |
severe asthma | 8 |
also include | 8 |
north african | 8 |
th century | 8 |
recent advances | 8 |
measurement properties | 8 |
polymerase chain | 8 |
posted april | 8 |
diagnostic model | 8 |
terrorism events | 8 |
good practices | 8 |
chow diet | 8 |
first case | 8 |
increasing number | 8 |
mammographic density | 8 |
must also | 8 |
supplementing broiler | 8 |
international pharmacopoeia | 8 |
target cells | 8 |
group agent | 8 |
manufacturing practice | 8 |
relative risks | 8 |
average number | 8 |
health laws | 8 |
issues related | 8 |
international organization | 8 |
rabbits kept | 8 |
political support | 8 |
people may | 8 |
north africa | 8 |
next wave | 8 |
additional copper | 8 |
findings will | 8 |
done using | 8 |
health programme | 8 |
competition law | 8 |
oral gavage | 8 |
bidding process | 7 |
chd deaths | 7 |
income inequality | 7 |
three days | 7 |
refugee crisis | 7 |
large extent | 7 |
common interest | 7 |
loaded nanoparticles | 7 |
age years | 7 |
new research | 7 |
protection working | 7 |
mammalian mirnas | 7 |
large scale | 7 |
close collaboration | 7 |
health inequalities | 7 |
three major | 7 |
lesser extent | 7 |
primary health | 7 |
copd patients | 7 |
sensitive data | 7 |
coronavirus crisis | 7 |
possible role | 7 |
technological progress | 7 |
molecular biology | 7 |
recently published | 7 |
also occur | 7 |
demographic characteristics | 7 |
many european | 7 |
paediatric patients | 7 |
progress towards | 7 |
world wide | 7 |
rome convention | 7 |
supplementing pig | 7 |
broilers slaughtered | 7 |
digestion system | 7 |
mycobacterium tuberculosis | 7 |
preclinical studies | 7 |
breast density | 7 |
examine whether | 7 |
also help | 7 |
medicines shortages | 7 |
vascular access | 7 |
bee pollen | 7 |
control subjects | 7 |
discrimination law | 7 |
publication bias | 7 |
gene regulation | 7 |
last months | 7 |
data subjects | 7 |
diagnostic tool | 7 |
early postoperative | 7 |
may act | 7 |
technical working | 7 |
three different | 7 |
rna recombination | 7 |
allergic disease | 7 |
acute pancreatitis | 7 |
pcr analysis | 7 |
mainland china | 7 |
sirna formulated | 7 |
human cells | 7 |
evolutionary history | 7 |
european industrial | 7 |
free survival | 7 |
hay fever | 7 |
detection methods | 7 |
mammalian mirna | 7 |
significant role | 7 |
specific topic | 7 |
human resource | 7 |
elective surgery | 7 |
final report | 7 |
higher prevalence | 7 |
intestinal permeability | 7 |
posted october | 7 |
seven european | 7 |
diseases will | 7 |
patient characteristics | 7 |
eu legislation | 7 |
global terrorism | 7 |
many patients | 7 |
diagnostic value | 7 |
occupational allergic | 7 |
health promotion | 7 |
references found | 7 |
much lower | 7 |
information provided | 7 |
refresher course | 7 |
new wave | 7 |
ich activities | 7 |
energy sector | 7 |
major challenges | 7 |
skin prick | 7 |
world tourism | 7 |
per week | 7 |
marginal revenue | 7 |
newborn screening | 7 |
may serve | 7 |
tuomivirta hantula | 7 |
gmp inspection | 7 |
ncrna stability | 7 |
scientific knowledge | 7 |
much better | 7 |
important differences | 7 |
correct diagnosis | 7 |
sporting success | 7 |
high spatial | 7 |
days ago | 7 |
team investments | 7 |
samples taken | 7 |
global market | 7 |
ich website | 7 |
raise awareness | 7 |
great importance | 7 |
inhibitory effect | 7 |
joint replacement | 7 |
retrospective study | 7 |
anaerobic bacteria | 7 |
environmental conditions | 7 |
saha yap | 7 |
tobacco smoke | 7 |
binding affinity | 7 |
provide evidence | 7 |
global markets | 7 |
valvular heart | 7 |
change adaptation | 7 |
working parties | 7 |
russian federation | 7 |
early childhood | 7 |
regulatory approval | 7 |
prevalence estimates | 7 |
current smoking | 7 |
major role | 7 |
emerging diseases | 7 |
regulatory decision | 7 |
level isolation | 7 |
secondary prevention | 7 |
pesticide exposure | 7 |
liability regime | 7 |
control program | 7 |
clinically relevant | 7 |
text content | 7 |
health technology | 7 |
economic policy | 7 |
may take | 7 |
institutional settings | 7 |
fat distribution | 7 |
productivity growth | 7 |
feed area | 7 |
market participants | 7 |
cow milk | 7 |
national institute | 7 |
intestinal microflora | 7 |
concentration mg | 7 |
likely due | 7 |
southern countries | 7 |
ct studies | 7 |
digital mammography | 7 |
human cases | 7 |
carbon economy | 7 |
orphan medicinal | 7 |
also present | 7 |
congenital malformations | 7 |
organised violence | 7 |
information related | 7 |
contact rates | 7 |
human health | 7 |
several times | 7 |
chd patients | 7 |
similar effects | 7 |
carotid artery | 7 |
technical challenges | 7 |
leading cause | 7 |
studies indicate | 7 |
cranial fossa | 7 |
european studies | 7 |
automotive industry | 7 |
expression levels | 7 |
clinical outcomes | 7 |
many others | 7 |
high number | 7 |
acute aortic | 7 |
representative sample | 7 |
bilateral collaboration | 7 |
trace elements | 7 |
innovation programme | 7 |
correlation matrix | 7 |
showed similar | 7 |
breast lesions | 7 |
pathological findings | 7 |
group housing | 7 |
soft tissues | 7 |
pulmonary arterial | 7 |
death model | 7 |
bat origin | 7 |
general practitioners | 7 |
study included | 7 |
countries covered | 7 |
rdrp sequences | 7 |
plant rnas | 7 |
additional imaging | 7 |
patients may | 7 |
school closures | 7 |
induced consumption | 7 |
genetic drift | 7 |
across different | 7 |
share information | 7 |
fed pigs | 7 |
basic principles | 7 |
minimum spanning | 7 |
health risks | 7 |
key findings | 7 |
acid levels | 7 |
general principles | 7 |
pressure values | 7 |
smoking status | 7 |
much less | 7 |
kingdom regulation | 7 |
peritoneal dialysis | 7 |
relevant studies | 7 |
compensatory criteria | 7 |
mirna mir | 7 |
brain imaging | 7 |
several factors | 7 |
may differ | 7 |
study provides | 7 |
mostly due | 7 |
rebound effects | 7 |
export bans | 7 |
safety data | 7 |
drug delivery | 7 |
wild animals | 7 |
mirnas may | 7 |
working ability | 7 |
success rate | 7 |
intestinal tract | 7 |
chest wall | 7 |
product registration | 7 |
spillover effect | 7 |
scientific societies | 7 |
regional offices | 7 |
three european | 7 |
elective arthroplasty | 7 |
full integration | 7 |
cooperation among | 7 |
imaging data | 7 |
panel discussion | 7 |
hand hygiene | 7 |
design methods | 7 |
commercially available | 7 |
copper supplementation | 7 |
preventive measures | 7 |
hybrid imaging | 7 |
detergent industry | 7 |
seroprevalence rate | 7 |
tumour tissue | 7 |
health legislation | 7 |
chek delc | 7 |
viral diseases | 7 |
translational repression | 7 |
syndrome virus | 7 |
differences across | 7 |
disease processes | 7 |
functional outcomes | 7 |
sensitivity analyses | 7 |
natural capital | 7 |
less efficient | 7 |
cooperation group | 7 |
eu law | 7 |
imaging probes | 7 |
global production | 7 |
international markets | 7 |
based small | 7 |
trust marks | 7 |
high school | 7 |
enzyme activity | 7 |
mature mirnas | 7 |
detailed knowledge | 7 |
monoclonal antibodies | 7 |
early warning | 7 |
passenger strand | 7 |
incubation period | 7 |
markov chain | 7 |
internal validity | 7 |
plasma membrane | 7 |
zona pellucida | 7 |
interested parties | 7 |
mri examination | 7 |
end points | 7 |
mean follow | 7 |
local control | 7 |
child birth | 7 |
transmission tree | 7 |
clinical management | 7 |
gi conditions | 7 |
patients will | 7 |
universal health | 7 |
low abundance | 7 |
ml min | 7 |
drug use | 7 |
policy response | 7 |
smoking behaviour | 7 |
tumour progression | 7 |
biological activity | 7 |
gini coefficient | 7 |
class outside | 7 |
resource management | 7 |
broadcasting income | 7 |
provide appropriate | 7 |
oncologic patients | 7 |
negative results | 7 |
scientific assessment | 7 |
will result | 7 |
global development | 7 |
health conditions | 7 |
digestive tract | 7 |
investigated whether | 7 |
positive effect | 7 |
associate partners | 7 |
worldwide basis | 7 |
will ultimately | 7 |
first meeting | 7 |
patients diagnosed | 7 |
quality standards | 7 |
hubei province | 7 |
per se | 7 |
organ tissues | 7 |
organic bound | 7 |
organic solvents | 7 |
important aspect | 7 |
three times | 7 |
medium term | 7 |
cu citrate | 7 |
legal requirements | 7 |
image interpretation | 7 |
social security | 7 |
taking place | 7 |
study shows | 7 |
clinical development | 7 |
advanced therapies | 7 |
western european | 7 |
using either | 7 |
analysis using | 7 |
pharmaceutical legislation | 7 |
zoonotic viruses | 7 |
climate neutrality | 7 |
green transition | 7 |
diabetes care | 7 |
obtained using | 7 |
different routes | 7 |
induced colitis | 7 |
posterior support | 7 |
accessed june | 7 |
family members | 7 |
rapidly cleared | 7 |
negative effect | 7 |
especially important | 7 |
swine fever | 7 |
structural changes | 7 |
food products | 7 |
central banks | 7 |
efficient technologies | 7 |
mobility reports | 7 |
major topics | 7 |
confidentiality agreements | 7 |
trials directive | 7 |
academic institutions | 7 |
irregular migrants | 7 |
article data | 7 |
fatty liver | 7 |
urgent need | 7 |
animal model | 7 |
human serum | 7 |
pacific region | 7 |
assess whether | 7 |
one another | 7 |
myocardial perfusion | 7 |
counterfeit medicines | 7 |
social care | 7 |
healthcare system | 7 |
research projects | 7 |
civil contingencies | 7 |
rabbits may | 7 |
signal intensity | 7 |
strategic plan | 7 |
disease outbreaks | 7 |
also suggests | 7 |
facial nerve | 7 |
effective way | 7 |
rebound effect | 7 |
migration rate | 7 |
rabies virus | 7 |
bacillus subtilis | 7 |
smoking cessation | 7 |
early diagnosis | 7 |
rfid technology | 7 |
new medicines | 7 |
eu steel | 7 |
association studies | 7 |
sample size | 7 |
every country | 7 |
interfering rna | 7 |
sierra leone | 7 |
imaging technologies | 7 |
media hub | 7 |
productive base | 7 |
diamond princess | 7 |
guide strand | 7 |
natural disasters | 7 |
step forward | 7 |
excluded references | 7 |
one nesting | 7 |
political economy | 7 |
ich guideline | 7 |
ct may | 7 |
human capital | 7 |
also consider | 7 |
steel community | 7 |
protection legislation | 7 |
surgical resection | 7 |
pulmonary hypertension | 7 |
migratory flows | 7 |
many areas | 7 |
will come | 7 |
data points | 7 |
dublin regulation | 7 |
plant small | 7 |
broilers layers | 7 |
european convention | 7 |
waist circumference | 7 |
vulnerable groups | 7 |
takes place | 7 |
price gouging | 7 |
environmental regulations | 7 |
liver cirrhosis | 7 |
education systems | 7 |
broadcasting rights | 7 |
elderly people | 7 |
player registrations | 7 |
final rating | 7 |
tumour cells | 7 |
make sure | 7 |
malignant tumours | 7 |
birth rate | 7 |
appropriate imaging | 7 |
target tissues | 7 |
noncommunicable diseases | 7 |
us stock | 7 |
hemorrhagic fever | 7 |
zero probability | 7 |
new drugs | 7 |
widely accepted | 7 |
reported deaths | 7 |
national policies | 7 |
data controller | 7 |
commons attribution | 7 |
wild type | 7 |
longitudinal studies | 7 |
annual report | 7 |
child protection | 7 |
conditions may | 7 |
benign lesions | 7 |
studied using | 7 |
increased mortality | 7 |
diseases may | 7 |
habitual residence | 7 |
workers exposed | 7 |